Jiangxi Bio Wins Securities Star’s “Industry Influence Award” | Deepening Industry Expertise to Set a Benchmark

An industry accolade stands as a testament to the company’s steadfast, long-term commitment and reflects the recognition and support of its peers. 

11 month 6 On [date], at the 14th Securities Star Capital Power Annual Awards Event, Jiangxi Bio ( 6915.HK ) awarded 2026 Year “Industry Influence Award.”

Image: The 14th Securities Star Capital Power Annual Awards – “Industry Influence Award” List

The Securities Star Capital Power Annual Awards have been held since 2012 Launched this year, the initiative continues to spotlight the growth and contributions of outstanding companies, serving as a key platform for the capital markets to identify long-term value and showcase industry benchmarks. With the theme “Climbing Higher Without Limits, Vision Unbounded,” this edition integrates market feedback with expert insights. Through a comprehensive assessment combining online voting, public sentiment indices, and professional judging, it selects leading financial institutions and listed companies across eight core sectors—listed firms, banking, insurance, and securities—providing valuable reference points for the capital markets.

This award recognizes Jiangxi Bio’s industrial strength, research innovation, and contributions to the industry in the field of equine‑derived polyclonal antibodies.

Photo: Jiangxi Bio Wins the 2026 “Industry Influence Award”

Cultivate niche industries and build leading global supply capabilities.

In the long and demanding field of equine‑derived polyclonal antibodies—a sector characterized by high industrial and technological barriers that requires considerable patience—Jiangxi Bio has adopted a steadfast, meticulous approach, seamlessly integrating every link in the value chain, from horse breeding and antigen development to antibody production and clinical applications. As a result, it has become one of the few companies worldwide with end‑to‑end, fully integrated supply‑chain capabilities.

Leveraging the collaborative advantages of its fully integrated industrial chain, the Group has established a comprehensive system spanning product R&D, manufacturing, and global supply, thereby advancing its flagship equine-derived polyclonal antibody product—human tetanus antitoxin (for human use). TAT ) Expand into international markets to achieve the world’s highest market share in product sales and the highest export ratio among Chinese companies. 

Currently, the Group has established coverage of 30 Sales networks in countries and regions, for human use TAT In both the Egyptian and Philippine local markets, its market share exceeds 90% and won government procurement contracts in several countries, including Ethiopia, Togo, and Mongolia. Ongoing market expansion and product supply have further enhanced the reputation of “Jiangxi Bio Human Use” TAT the international brand influence of “. 

Activating the driving force of technological innovation and pioneering the diversified development of polyclonal antibodies. 

In recent years, Jiangxi Bio has consistently upheld the philosophy of “quality as the anchor, innovation as the wing,” actively iterating its existing product manufacturing processes, leveraging the platform advantages of equine-derived polyclonal antibody technology, and integrating cutting-edge biotechnologies to advance the development of additional pipeline candidates. 

The group is domestically used in humans TAT It is the first company in the field to adopt the “three-in-one” technology of preservative-free, virus-inactivated, and vial-packaged formulations, and it is also the only one worldwide to use recombinant proteins, m RNA and companies developing antiserum products without serum antigens. The project “Innovative Full-Chain Technology System for High-Purity Tetanus Antitoxin and Its Industrial Application,” led by the group, has won 2025 It won the Second Prize of the Jiangxi Provincial Technological Invention Award and became part of Ji’an City, Jiangxi Province. 2025 Annual Provincial Science and Technology Awards 10 One of the achievements. 

From refining the manufacturing processes of existing products to “human medicines” + Through the continued expansion of its dual‑pillar veterinary pharmaceutical pipeline, the Group is steadily extending innovation to the very source of R&D and advancing “ AI+ Fusion protein mRNA Antigen Development Platform and Equine Source F(ab’) ₂ The development of a process platform, integrating digitalization and smart manufacturing capabilities, fosters collaboration between R&D and production, providing platform support for the technological upgrade and product development of equine-derived polyclonal antibodies. 

Building on its longstanding expertise and maintaining a steady pace of innovation, Jiangxi Bio is focusing on four key areas—viral infections, bacterial infections, biotoxin poisoning, and immune modulation—to continuously expand the applications of equine polyclonal antibodies in human medicine and animal health, while exploring diverse avenues for their further development. 

“Climbing high never ends; gazing far knows no bounds.”

In the future, Jiangxi Bio will consolidate its human-use TAT Building on its global leadership, the company will further leverage its pioneering role, strengthen its position as an industry benchmark through in-depth cultivation of its core sectors, and drive the implementation of more products and applications through technological innovation, thereby contributing practical experience to the diversified development of the monoclonal antibody industry.